|Day Low/High||68.93 / 70.28|
|52 Wk Low/High||68.91 / 110.81|
It becomes difficult for me to tell you where to run in these markets...
Upcoming results from these names -- and many others -- should reassure investors.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
With biotech names getting some attention this morning a quick review looks like a good idea.
Taking the measure of what's keeping the markets in the dumps.
After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.
The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...
The Chinese have something to lose here, and will not willingly surrender their position of superiority in trade.
It is good once again to be sitting in for Doug Kass on a Friday here on the Daily Diary. Going to be a busy day as we get the monthly jobs report coming out in just over an hour. Although GDP growth (2.3%) did slow in the first quarter from the 3% ...
Data and industry conferences will likely be catalysts for shares in the space.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
A look at possible second-quarter M&A activity in the biotech sector.
Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
From ANI Pharmaceuticals to T2 Biosystems, these names look good.
Recently I have noticed some of Wall Street's younger analysts engaging in "multiple creep." They seem to be treating a 12 EBITD (cash flow) multiple like a 12 PE (price to earnings) ratio. Whoops! No problem, for example, paying 25x EPS for ....Unt...
I continue to deploy some of the 'dry powder' into the market after its recent hiccup.